GO:0004617 phosphoglycerate dehydrogenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004617 phosphoglycerate dehydrogenase activity catalyzes the NAD+-dependent oxidation of 3-phosphoglycerate to 3-phosphohydroxypyruvate, the first committed step of de novo serine synthesis.
• The enzyme is encoded by PHGDH in humans and is a member of the D-3-phosphoglycerate dehydrogenase family, with a characteristic substrate-binding domain and NAD+ cofactor requirement.
• PHGDH activity supports serine and one-carbon metabolism, influencing nucleotide synthesis, redox balance, and epigenetic regulation.
• Dysregulated PHGDH activity is implicated in multiple cancers, including hepatocellular carcinoma, prostate cancer, and others, where it promotes tumor growth and therapy resistance.
• PHGDH also plays roles in non-cancer contexts such as macrophage IL-1β production, cellular senescence, and Alzheimer's disease pathology.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential for dissecting the causal roles of PHGDH and its regulatory network in health and disease.
Description
Phosphoglycerate dehydrogenase (PHGDH) is the rate-limiting enzyme in the de novo serine biosynthesis pathway, catalyzing the NAD+-dependent conversion of 3-phosphoglycerate to 3-phosphohydroxypyruvate. This reaction, annotated as GO:0004617, represents the first committed step that diverts glycolytic intermediates toward serine production, a critical node for one-carbon metabolism, nucleotide synthesis, and antioxidant defense. Beyond its metabolic role, PHGDH has emerged as a multifunctional protein involved in transcriptional regulation, RNA stability, and protein acetylation, linking serine synthesis to diverse cellular processes. Researchers study GO:0004617 because its dysregulation is associated with a wide range of human diseases, including cancer, neurodegenerative disorders, and metabolic syndromes. In cancer, PHGDH amplification or overexpression supports tumor growth by sustaining serine supply and redox homeostasis, and its inhibition can induce ferroptosis or overcome therapy resistance. In macrophages, serine synthesis sustains IL-1β production via NAD+-dependent protein acetylation, highlighting its role in inflammation. In Alzheimer's disease, PHGDH transcriptional regulation drives amyloid pathology, suggesting a direct link between serine metabolism and neurodegeneration. Thus, understanding the molecular mechanisms, regulation, and disease relevance of GO:0004617 is essential for developing targeted therapeutic strategies. This article provides a comprehensive overview of phosphoglycerate dehydrogenase activity, covering its definition, catalytic mechanism, key genes, regulatory networks, disease associations, and the CRISPR-based models and methods used to study it. By integrating authoritative QuickGO annotations with verified PubMed literature, we aim to equip researchers with a robust framework for investigating this critical enzyme.
phosphoglycerate dehydrogenase activity At A Glance
| GO ID | GO:0004617 |
|---|---|
| GO term | phosphoglycerate dehydrogenase activity |
| Ontology | molecular_function |
| Synonym | 3-phospho-D-glycerate:NAD+ 2-oxidoreductase activity; 3-phosphoglycerate dehydrogenase activity; D-3-phosphoglycerate dehydrogenase activity; PGDH activity; SerA |
| Major function | Catalyzes the NAD+-dependent oxidation of 3-phosphoglycerate to 3-phosphohydroxypyruvate, the first step in de novo serine biosynthesis |
| Reaction | 3-phosphoglycerate + NAD+ = 3-phosphohydroxypyruvate + NADH + H+ |
| Cofactor | NAD+ |
| Substrate | 3-phosphoglycerate |
| Product | 3-phosphohydroxypyruvate |
| Pathway | Serine biosynthesis (de novo) |
What Is GO:0004617?
GO:0004617 phosphoglycerate dehydrogenase activity is defined as the catalysis of the reaction: 3-phosphoglycerate + NAD+ = 3-phosphohydroxypyruvate + NADH + H+. This oxidoreductase activity is central to serine biosynthesis, utilizing NAD+ as an electron acceptor to oxidize 3-phosphoglycerate, yielding 3-phosphohydroxypyruvate and reducing NAD+ to NADH.
Why Is phosphoglycerate dehydrogenase activity Important in Cell Biology?
Phosphoglycerate dehydrogenase activity is a critical metabolic valve that links glycolysis to serine biosynthesis, influencing fundamental processes such as nucleotide production, methylation reactions, and cellular redox balance. Its dysregulation is directly implicated in cancer progression, where it supports tumor growth and therapy resistance, as well as in inflammatory responses and neurodegenerative diseases. Consequently, understanding its regulation and function is vital for developing targeted interventions in oncology and beyond.
• Rate-limiting enzyme for de novo serine synthesis, essential for cell proliferation.
• Supports one-carbon metabolism and nucleotide biosynthesis.
• Maintains redox homeostasis by contributing to glutathione synthesis.
• Implicated in multiple cancers, including hepatocellular carcinoma and prostate cancer.
• Regulates macrophage IL-1β production via NAD+-dependent acetylation.
• Plays a role in cellular senescence through PKM2 activation.
• Associated with Alzheimer's disease amyloid pathology.
• Target for ferroptosis induction in therapy-resistant cancers.
• Subject to complex regulation by ubiquitination and transcriptional control.
• Provides a metabolic vulnerability for precision medicine.
Mechanism, Genes and Research Methods
Substrate Binding and Catalysis
In simple terms: The enzyme grabs 3-phosphoglycerate and uses NAD+ to remove electrons, creating a new molecule.
Phosphoglycerate dehydrogenase binds its substrate, 3-phosphoglycerate, in a cleft formed by the substrate-binding domain. The catalytic mechanism involves hydride transfer from the substrate to NAD+, forming NADH and 3-phosphohydroxypyruvate. This oxidation is the first committed step in serine biosynthesis, and the enzyme's activity is tightly regulated to meet cellular demands for serine and its derivatives.
Cofactor Requirement and Redox Balance
In simple terms: NAD+ is a helper molecule that accepts electrons during the reaction, becoming NADH.
The reaction catalyzed by GO:0004617 strictly requires NAD+ as a cofactor. The reduction of NAD+ to NADH couples serine synthesis to the cellular redox state, and the resulting NADH can influence other metabolic pathways, including those involved in antioxidant defense and protein acetylation. This redox coupling positions PHGDH as a sensor of metabolic flux.
Structural Organization of PHGDH
In simple terms: The enzyme is made of several parts that work together to bind substrates and catalyze the reaction.
Human PHGDH is a tetrameric enzyme composed of subunits that each contain a substrate-binding domain, a nucleotide-binding domain, and a regulatory domain. The active site is formed at the interface of these domains, and conformational changes upon substrate binding facilitate catalysis. Mutations in these domains can alter enzyme activity and are linked to serine deficiency disorders.
Regulation by Post-Translational Modifications
In simple terms: Cells can attach small tags to the enzyme to control its activity or stability.
PHGDH activity is modulated by post-translational modifications, including ubiquitination and acetylation. For example, FBXO7 ubiquitinates PRMT1 to suppress serine synthesis, indirectly affecting PHGDH function. Additionally, PHGDH can be stabilized by interactions with other proteins, such as protein kinase C delta type mRNA, which promotes hepatocellular carcinoma progression. These modifications fine-tune serine synthesis in response to cellular signals.
Integration with Signaling Pathways
In simple terms: The enzyme's activity is connected to growth signals and stress responses.
PHGDH is regulated by oncogenic signaling pathways, including mTOR and ATF4, which promote its expression under conditions of high demand for serine. In macrophages, serine synthesis sustains IL-1β production via NAD+-dependent protein acetylation, linking PHGDH activity to inflammatory signaling. In Alzheimer's disease, transcriptional regulation of PHGDH drives amyloid pathology, indicating a role in neurodegeneration.
Key Genes Involved in GO:0004617 phosphoglycerate dehydrogenase activity
The following genes and proteins are directly or indirectly involved in phosphoglycerate dehydrogenase activity and its regulatory network.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PHGDH | Encodes the enzyme catalyzing GO:0004617; rate-limiting for serine synthesis | Target for cancer therapy, metabolic studies, and disease modeling |
| PSAT1 | Converts 3-phosphohydroxypyruvate to phosphoserine in serine synthesis | Downstream enzyme, often co-regulated with PHGDH |
| PSPH | Dephosphorylates phosphoserine to serine | Final step of serine synthesis, linked to PHGDH flux |
| SHMT1/2 | Serine hydroxymethyltransferases, feed one-carbon metabolism | Integrate serine synthesis with nucleotide production |
| MTHFD1/2 | One-carbon metabolism enzymes | Support purine synthesis and methylation |
| PKM2 | Pyruvate kinase M2, interacts with PHGDH | Mediates senescence regulation via histone phosphorylation |
| PRMT1 | Protein arginine methyltransferase, regulated by FBXO7 | Suppresses serine synthesis and tumor growth |
| FBXO7 | E3 ubiquitin ligase, targets PRMT1 | Regulates PHGDH pathway in hepatocellular carcinoma |
| ATF4 | Stress-responsive transcription factor | Induces PHGDH expression under ER stress |
| mTOR | Growth signaling kinase | Promotes serine synthesis via PHGDH regulation |
| PKCδ | Protein kinase C delta type | PHGDH stabilizes its mRNA in HCC |
| IL-1β | Pro-inflammatory cytokine | Production sustained by serine synthesis in macrophages |
| Amyloid-beta | Peptide involved in Alzheimer's disease | PHGDH transcriptional regulation drives amyloid pathology |
| NAD+ | Cofactor for PHGDH reaction | Links serine synthesis to redox and acetylation |
| Serine | End product of pathway | Essential for nucleotide, glutathione, and protein synthesis |
| 3-phosphoglycerate | Substrate for PHGDH | Glycolytic intermediate diverted to serine synthesis |
| 3-phosphohydroxypyruvate | Product of PHGDH reaction | Intermediate in serine biosynthesis |
| Enzalutamide | Androgen receptor antagonist | Resistance overcome by PHGDH inhibition |
How Is phosphoglycerate dehydrogenase activity Regulated?
Phosphoglycerate dehydrogenase activity is regulated at multiple levels. Transcriptionally, PHGDH is induced by ATF4 in response to stress and by oncogenic signals such as mTOR. Post-translationally, ubiquitination by FBXO7 targets PRMT1, which in turn suppresses serine synthesis, indirectly affecting PHGDH. Additionally, PHGDH protein stability can be modulated by interactions with mRNA-binding proteins, as seen in hepatocellular carcinoma where PHGDH stabilizes PKCδ mRNA. Metabolic feedback loops involving serine and NAD+ also influence enzyme activity.
phosphoglycerate dehydrogenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PHGDH | Hepatocellular carcinoma | PHGDH knockout or overexpression in HCC cell lines |
| PHGDH | Castration-resistant prostate cancer | PHGDH inhibition in enzalutamide-resistant cells |
| PHGDH | Alzheimer's disease | PHGDH knockdown in neuronal models |
| PHGDH | Serine deficiency disorders | Patient-derived fibroblasts or knock-in mice |
| PHGDH | Macrophage IL-1β production | Macrophage-specific PHGDH knockout |
Cancer
PHGDH is frequently overexpressed in cancers, including hepatocellular carcinoma, prostate cancer, and others, where it supports tumor growth by sustaining serine synthesis and redox balance. Inhibition of PHGDH induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells. In hepatocellular carcinoma, PHGDH stabilizes PKCδ mRNA to promote progression, and its ubiquitination by FBXO7 suppresses tumor growth.
Neurodegeneration
In Alzheimer's disease, transcriptional regulation of PHGDH drives amyloid pathology, suggesting that dysregulated serine metabolism contributes to neurodegeneration. Additionally, serine deficiency disorders, which can result from mutations in PHGDH, cause neurological symptoms such as seizures and developmental delay.
Inflammation and Immunity
Serine synthesis via PHGDH sustains macrophage IL-1β production through NAD+-dependent protein acetylation, linking metabolic activity to inflammatory responses. This highlights PHGDH as a potential target for modulating immune responses.
Cellular Senescence
PHGDH activates PKM2 to phosphorylate histone H3T11, attenuating cellular senescence. This function connects serine metabolism to epigenetic regulation and aging-related processes.
From phosphoglycerate dehydrogenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PHGDH loss affect tumor growth? | PHGDH knockout cell lines and xenografts |
| How does a specific PHGDH mutation alter enzyme activity? | Point mutation knock-in via CRISPR |
| What is the effect of PHGDH overexpression on serine levels? | PHGDH overexpression cell lines |
| Where is PHGDH localized in cells? | Tagged knock-in with fluorescent protein |
| Does PHGDH regulate macrophage inflammation? | Conditional knockout in macrophages |
| Can PHGDH inhibition overcome drug resistance? | PHGDH knockout in resistant cancer cells |
How to Study the phosphoglycerate dehydrogenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | NADH production | Validate PHGDH mutants or inhibitors |
| 13C metabolic tracing | Flux through serine synthesis | Quantify pathway activity in cancer cells |
| CRISPR knockout screen | Gene essentiality and interactions | Identify regulators of PHGDH dependency |
| RNA-seq | Transcriptional changes | Assess PHGDH expression and pathway genes |
| Proteomics | Protein abundance and modifications | Detect PHGDH post-translational changes |
| Western blot | Protein levels | Confirm knockout or overexpression |
| Immunofluorescence | Subcellular localization | Visualize PHGDH in cells |
| Xenograft models | Tumor growth in vivo | Test PHGDH targeting in cancer |
Enzyme Activity Assays
Direct measurement of phosphoglycerate dehydrogenase activity is performed using spectrophotometric assays that monitor NADH production at 340 nm. These assays use purified enzyme or cell lysates and are essential for validating the functional impact of mutations or inhibitors.
Metabolic Flux Analysis
Stable isotope tracing with 13C-labeled glucose or serine can quantify flux through the serine synthesis pathway. This method reveals how PHGDH activity contributes to metabolic reprogramming in cancer and other diseases.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout screens can identify genes that modulate PHGDH dependency or serine synthesis. Such screens have uncovered regulators like FBXO7 and PRMT1.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics can assess changes in PHGDH expression and downstream pathways upon genetic or pharmacological perturbation. These approaches help elucidate the broader regulatory network.
How CRISPR Can Be Used to Study GO:0004617 phosphoglycerate dehydrogenase activity
Knockout
CRISPR knockout of PHGDH is used to abolish enzyme activity and study its role in serine synthesis, cell proliferation, and tumor growth. Knockout cell lines have demonstrated that PHGDH loss induces ferroptosis and sensitizes cancer cells to therapy.
Point Mutation
Point mutations in the PHGDH catalytic domain can be introduced via CRISPR to dissect the contribution of specific residues to substrate binding and catalysis. Such models help validate enzyme mechanism and identify loss-of-function variants associated with serine deficiency disorders.
Knock-in
Knock-in of tagged PHGDH (e.g., GFP or FLAG) allows for real-time tracking of protein localization and interaction partners. This approach is valuable for understanding PHGDH dynamics in live cells.
Overexpression
CRISPR activation or cDNA overexpression of PHGDH is used to model its upregulation in cancers and to study the consequences of increased serine synthesis on metabolism and gene expression.
How EDITGENE Supports phosphoglycerate dehydrogenase activity Research
Researchers studying phosphoglycerate dehydrogenase activity-related genes often need to determine whether a candidate gene is causally involved in a specific metabolic or disease phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for phosphoglycerate dehydrogenase activity research.
Frequently Asked Questions About phosphoglycerate dehydrogenase activity
What is phosphoglycerate dehydrogenase activity?
It is the enzyme activity that catalyzes the NAD+-dependent conversion of 3-phosphoglycerate to 3-phosphohydroxypyruvate, the first step in serine biosynthesis.
What gene encodes phosphoglycerate dehydrogenase?
The PHGDH gene encodes the human enzyme responsible for this activity.
What is the GO ID for phosphoglycerate dehydrogenase activity?
The Gene Ontology ID is GO:0004617.
What diseases are associated with PHGDH?
PHGDH is linked to cancers such as hepatocellular carcinoma and prostate cancer, as well as Alzheimer's disease and serine deficiency disorders.
How is PHGDH activity regulated?
It is regulated transcriptionally by ATF4 and mTOR, and post-translationally by ubiquitination and interactions with other proteins.
What are the substrates and products of PHGDH?
The substrate is 3-phosphoglycerate and the products are 3-phosphohydroxypyruvate and NADH.
Can PHGDH be targeted for cancer therapy?
Yes, inhibition of PHGDH induces ferroptosis and overcomes enzalutamide resistance in prostate cancer, making it a promising therapeutic target.
What role does PHGDH play in macrophages?
Serine synthesis via PHGDH sustains IL-1β production through NAD+-dependent protein acetylation.
How does PHGDH affect cellular senescence?
PHGDH activates PKM2 to phosphorylate histone H3T11, attenuating cellular senescence.
What CRISPR models are available for studying PHGDH?
Knockout, point mutation, knock-in, and overexpression models can be generated to study PHGDH function in various contexts.
Conclusion
Phosphoglycerate dehydrogenase activity (GO:0004617) is a fundamental metabolic function that bridges glycolysis and serine biosynthesis, with far-reaching implications for cancer, neurodegeneration, and inflammation. Its regulation is complex, involving transcriptional, post-translational, and metabolic inputs. The use of CRISPR-based models and advanced analytical methods continues to unravel its roles in health and disease, offering opportunities for therapeutic intervention. EDITGENE provides the tools and expertise to accelerate this research.
References
- 1. Wu Y et al.. 2023. Phosphoglycerate dehydrogenase activates PKM2 to phosphorylate histone H3T11 and attenuate cellular senescence.. Nat Commun 14(1):1323 PMID: 36899022
- 2. Grant GA. 2018. D-3-Phosphoglycerate Dehydrogenase.. Front Mol Biosci 5:110 PMID: 30619878
- 3. Wang C et al.. 2024. Serine synthesis sustains macrophage IL-1β production via NAD(+)-dependent protein acetylation.. Mol Cell 84(4):744-759.e6 PMID: 38266638
- 4. Chen J et al.. 2025. Transcriptional regulation by PHGDH drives amyloid pathology in Alzheimer's disease.. Cell 188(13):3513-3529.e26 PMID: 40273909
- 5. Wang J et al.. 2023. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells.. Drug Resist Updat 70:100985 PMID: 37423117
- 6. Cheng B et al.. 2025. Phosphoglycerate dehydrogenase stabilizes protein kinase C delta type mRNA to promote hepatocellular carcinoma progression.. Signal Transduct Target Ther 10(1):236 PMID: 40681503
- 7. Luo L et al.. 2024. FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma.. Nat Commun 15(1):4790 PMID: 38839752
- 8. Adam MP et al.. 1993. Serine Deficiency Disorders.. PMID: 37347880
